Clinical Trials Logo

Filter by:
NCT ID: NCT00898326 Completed - Prostate Cancer Clinical Trials

PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer

SHIP36B
Start date: April 1, 2011
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tissue from patients with prostate cancer after receiving implant radiation therapy and luteinizing hormone-releasing hormone agonist may help doctors identify biomarkers related to cancer and help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at PSA levels and biopsy samples after undergoing implant radiation therapy and luteinizing hormone-releasing hormone agonist therapy in patients with stage I or stage II prostate cancer.

NCT ID: NCT01158118 Completed - Multiple Myeloma Clinical Trials

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Start date: April 1, 2011
Phase: Phase 2
Study type: Interventional

This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide enough stem cells for transplantation and may also reduce the risk of graft versus host disease.

NCT ID: NCT01190189 Completed - Clinical trials for Infections, Papillomavirus

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Start date: April 1, 2011
Phase: Phase 3
Study type: Interventional

This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in countries for which the licensed GSK HPV vaccine is not indicated for the subject's age group (26 years and older). This study is thus conducted to enable all women who received the control placebo in the primary NCT00294047 study to receive the GSK580299 vaccine.

NCT ID: NCT01245049 Completed - Tetanus Clinical Trials

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

Start date: April 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and 4-year-old children.

NCT ID: NCT01253070 Completed - Clinical trials for Therapy-Related Acute Myeloid Leukemia

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Start date: April 1, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sorafenib tosylate and chemotherapy work in treating older patients with acute myeloid leukemia (AML). Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving sorafenib tosylate and combination chemotherapy may be an effective treatment for AML.

NCT ID: NCT01259869 Completed - Glioblastoma Clinical Trials

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Start date: April 1, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.

NCT ID: NCT01286623 Completed - HIV Infection Clinical Trials

The Pharmacology/Aging Clinic

SSAT041
Start date: April 1, 2011
Phase: N/A
Study type: Observational

The treatment of HIV and the tests performed for HIV care have changed over the last 20 years. However, improvement of management of HIV-infected subjects is still warranted, especially as the HIV-infected population is aging. Therefore, this study will involve the collection and analysis of clinical information obtained from subjects who are over 50 years of age. For example, patients' risk of heart disease will be measured and monitored by looking at blood tests and clinical data (such as blood pressure). This will allow researchers to understand if the current way of assessing the risk of future heart disease is the best one available for HIV-infected individuals. No genetic research will be done.

NCT ID: NCT01323959 Completed - Tetanus Clinical Trials

Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults

Start date: April 1, 2011
Phase: Phase 4
Study type: Interventional

This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another booster dose of BoostrixTM Polio.

NCT ID: NCT01324310 Completed - Clinical trials for Hematologic Malignancy

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Start date: April 1, 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect and safety of multiple doses of ketoconazole on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

NCT ID: NCT01324323 Completed - Clinical trials for Hematologic Malignancy

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Start date: April 1, 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.